CompletedPhase 2NCT02592798

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Studying Non-genetic systemic disease with glomerulopathy as a major feature

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bristol-Myers Squibb
Principal Investigator
Bristol Myers Squibb
Bristol-Myers Squibb
Intervention
Abatacept(drug)
Enrollment
36 enrolled
Eligibility
6 years · All sexes
Timeline
20162020

Study locations (27)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02592798 on ClinicalTrials.gov

Other trials for Non-genetic systemic disease with glomerulopathy as a major feature

Additional recruiting or active studies for the same condition.

See all trials for Non-genetic systemic disease with glomerulopathy as a major feature

← Back to all trials